Guggenheim Securities Initiates Coverage on EDWARDS LIFE SCIENCES COM to Neutral

Guggenheim Securities Initiates Coverage on EDWARDS LIFE SCIENCES COM(NYSE:EW). The shares have been rated Neutral. The rating by Guggenheim Securities was issued on Jun 9, 2016.

In a different note, On Apr 27, 2016, Citigroup said it Maintains its rating on EDWARDS LIFE SCIENCES COM. In the research note, the firm Raises the price-target to $67.00 per share. The shares have been rated ‘Sell’ by the firm. On Apr 27, 2016, Cowen & Company said it Maintains its rating on EDWARDS LIFE SCIENCES COM. In the research note, the firm Raises the price-target to $105.00 per share. The shares have been rated ‘Outperform’ by the firm. On Apr 7, 2016, Barclays said it Maintains its rating on EDWARDS LIFE SCIENCES COM. In the research note, the firm Raises the price-target to $87.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On Apr 5, 2016, Northland Securities said it Downgrades its rating on EDWARDS LIFE SCIENCES COM. The shares have been rated ‘Market Perform’ by the firm. On Apr 4, 2016, JP Morgan said it Reiterates its rating on EDWARDS LIFE SCIENCES COM. In the research note, the firm Raises the price-target to $98.00 per share. The shares have been rated ‘Overweight’ by the firm. On Apr 4, 2016, BTIG Research said it Upgrades its rating on EDWARDS LIFE SCIENCES COM. The shares have been rated ‘Buy’ by the firm.

EDWARDS LIFE SCIENCES COM (EW) shares turned negative on Wednesdays trading session with the shares closing down -3.1 points or -3.07% at a volume of 31,00,175. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $101.79. The peak price level was also seen at $101.79 while the days lowest was $96.79. Finally the shares closed at $97.85. The 52-week high of the shares is $112 while the 52-week low is $62.53. According to the latest information available, the market cap of the company is $20,721 M.

EDWARDS LIFE SCIENCES COM(EW) last announced its earnings results on Apr 26, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $697.30M. Analysts had an estimated revenue of $664.85M. Earnings per share were $0.71. Analysts had estimated an EPS of $0.66.

Several Insider Transactions has been reported to the SEC. On Jun 7, 2016, Huimin Wang (CVP, Japan & Intercontinental) sold 13,650 shares at $101.50 per share price.Also, On Jun 6, 2016, Larry L Wood (CVP, THV Replacement) sold 13,257 shares at $101.34 per share price.On Jun 2, 2016, Donald E Jr Bobo (CVP, Heart Valve Therapy) sold 18,000 shares at $99.41 per share price, according to the Form-4 filing with the securities and exchange commission.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *